Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic Shares of Eliem Therapeutics fell more than 50% Monday after the company reported disappointing clinical data. Its compound to treat… Read More
Juno’s lasting legacy: How the cell therapy juggernaut influenced biotech in Seattle and beyond When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of… Read More
